Investors
Download Investor Presentation
Company Overview
Most Recent Shareholder Letter
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000...
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,”...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial...
Latest Annual Filing
Fiscal Year Ended Dec 31, 2020
Investor Contact Information
Company
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121
T: +1 858 923-4422
Investor Relations
T:
investors@aximbiotech.com
Transfer Agent
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com